论文部分内容阅读
1998年以来主要的研究发现:·对于脑血管疾病,小剂量阿司匹林(80～325mg)与较 高剂量阿司匹林(500～1 000mg)同样有效。·已经证实口服抗血小板药物氯吡格雷和静脉糖蛋 白Ⅱb/Ⅲa拮抗剂是重要的抗栓药物。·尚未发现口服的糖蛋白Ⅱb/Ⅲa受体拮抗剂对于 心肌缺血有效。·在冠状动脉支架置放的患者,与阿司匹林和噻氯匹定 一样,阿司匹林和氯吡格雷联合应用有协同作用。·对于急性冠状动脉缺血综合征和静脉血栓栓塞 (VTE)患者,低分子肝素(LMWH)是未级分肝素 (UFH)的有效替代。·房颤(AF)口服抗凝药物治疗范围的低限为国际标 准化比值(INR)2.0。·低强度华法林(固定的低剂量或INR<2.0)与阿司 匹林联合应用,并未证实对房颤患者有益。
Major studies since 1998 have found that: • For cerebrovascular disease, low-dose aspirin (80-325 mg) is as effective as higher-dose aspirin (500-1000 mg). Oral antiplatelet agents clopidogrel and intravenous glycoprotein IIb / IIIa antagonists have been shown to be important antithrombotic drugs. Oral glycoprotein IIb / IIIa receptor antagonists have not been found to be effective for myocardial ischemia. In patients with coronary stents, aspirin and clopidogrel have synergistic effects, as do aspirin and ticlopidine. Low molecular weight heparin (LMWH) is a valid alternative to unfractionated heparin (UFH) in patients with acute coronary syndromes and venous thromboembolism (VTE). · The lower limit of the therapeutic range of oral anticoagulant therapy for atrial fibrillation (AF) is the International Normalized Ratio (INR) of 2.0. Low-intensity warfarin (fixed low-dose or INR <2.0) in combination with aspirin has not been shown to benefit patients with AF.